Visugromab for cancer-related weight loss
Treatments studied
Part of Cancer clinical trials.
This trial tests a medicine called visugromab for people with advanced cancer who have also lost weight. It aims to help with that weight loss (cachexia) and potentially improve your quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lost some weight without trying.
- You have advanced cancer.
- You have not been in another clinical trial or taken any experimental drug in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
This trial tests a medicine called ponsegromab for people with advanced lung cancer who have lost significant weight (cachexia). If you qualify, you'll receive ponsegromab along with your first dose of durvalumab immunotherapy.
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
This trial tests a new drug, ASCA101, for people with certain cancers who are experiencing unwanted weight loss (cachexia). It aims to see if the drug can help improve appetite and stabilize weight. Participants must have colorectal, ovarian, or lung cancer and meet specific weight loss criteria.
This Phase 1 trial tests a new drug (AV-380) in people with solid tumor cancer who are losing weight and muscle because of cancer. It mainly helps researchers find a safe dose and see how the body responds, and it may offer a new option for cancer-related cachexia.
Hear when a new Cancer-associated Cachexia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.